Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.210
+0.085 (7.56%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Quince Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,578,556
Market Cap
54.12M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
QNCX News
- 24 days ago - Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference - Business Wire
- 4 weeks ago - Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
- 2 months ago - Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
- 2 months ago - Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 2 months ago - Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board - Business Wire